Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment.

Da, Liangshan; Qu, Ziting; Zhang, Congjun; Shen, Yuanyuan; Huang, Wei; Zhang, Yiyin; Gu, Kangsheng

Da, Liangshan; Qu, Ziting; Zhang, Congjun; Shen, Yuanyuan; Huang, Wei; Zhang, Yiyin; Gu, Kangsheng.

Afiliación

Da L; Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Qu Z; Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Zhang C; Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Shen Y; Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Huang W; Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Zhang Y; Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Gu K; Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Front Oncol ; 13: 1144875, 2023.

Article en En | MEDLINE | ID: mdl-37035159

Palabras clave

PD-1; esophageal squamous cell carcinoma; immunotherapy; inflammatory markers; prognosis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google